Mayo Clinic works with hundreds of insurance companies and is an in-network provider for millions of people. In most cases, Mayo Clinic doesn't require a physician referral. Some insurers require referrals or may have additional requirements for certain medical care. All appointments are prioritized on the basis of medical need.
For details about requesting an appointment for Choline C-11 PET scan in conjunction with evaluation for recurrent prostate cancer, please call 507-293-0933 from 8 a.m. to 5 p.m. Central time, Monday through Friday.
You must complete an initial evaluation in the Department of Urology before being considered for the Choline C-11 PET scan. Following the consult, a determination will be made regarding the appropriateness of the scan. If the Choline C-11 PET scan is recommended, a separate return visit will likely be required to conduct the scan. Access for this scan is limited by the ability to produce the Choline C-11 imaging agent and appointment availability.
The local contractor for the Centers for Medicare and Medicaid Services (CMS) has approved coverage of this scan for the indications of recurrent prostate cancer and biochemical recurrence of prostate cancer.
For all other appointment information at Mayo Clinic's campus in Rochester, see Appointments at Mayo Clinic in Rochester.
- U.S. Patients
- International Patients
Becoming a Patient
See information on patient services at the three Mayo Clinic locations, including transportation options and lodging.
Aug. 05, 2014
- FDA approves production of imaging agent that helps detect prostate cancer. U.S. Food and Drug Administration. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm319201.htm. Accessed April 15, 2014.
- Choline C-11 injection (prescribing information). Rochester, Minn. Mayo Clinic PET Radiochemistry Facility; 2012. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#labelinfo. Accessed April 15, 2014.
- Prostate cancer. Fort Washington, Pa.: National Comprehensive Cancer Network. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed April 15, 2014.
- Murphy RC, et al. The utility of 11C-Choline PET/CT for imaging prostate cancer: A pictorial guide. American Journal of Roentgenology. 2011;196:1390.
- Fuccio C, et al. Choline PET/CT for prostate cancer: Main clinical applications. European Journal of Radiology. 2011;80:50.
- Fox JJ, et al. Molecular imaging of prostate cancer. Current Opinion in Urology. 2012;22:320.
- Kitajima K, et al. Update on positron emission tomography for imaging of prostate cancer. International Journal of Urology. 2014;21:12.
- Mitchell CR, et al. Operational characteristics of 11C-Choline positron emission tomography/computerized tomography for prostate cancer with biochemical recurrence after initial treatment. The Journal of Urology. 2013;189:1308.
- Kwon ED (expert opinion). Mayo Clinic, Rochester, Minn. April 16, 2014.